Quarter Period Consolidated Statement Of Income

Oncolys BioPharma Inc. - Filing #7595769

Concept 2022-01-01 to
2022-06-30
2021-01-01 to
2021-06-30
Quarter period consolidated statement of income
Statement of income
Net sales
426,152,000 JPY
193,067,000 JPY
Cost of sales
186,697,000 JPY
53,516,000 JPY
Gross profit (loss)
239,454,000 JPY
139,551,000 JPY
Selling, general and administrative expenses
Remuneration for directors (and other officers)
46,626,000 JPY
125,544,000 JPY
Selling, general and administrative expenses
898,353,000 JPY
773,150,000 JPY
Operating profit (loss)
-658,898,000 JPY
-633,599,000 JPY
Non-operating income
Interest income
284,000 JPY
238,000 JPY
Non-operating income
84,641,000 JPY
25,437,000 JPY
Non-operating expenses
Interest expenses
1,937,000 JPY
2,109,000 JPY
Non-operating expenses
16,257,000 JPY
40,853,000 JPY
Ordinary profit (loss)
-590,514,000 JPY
-649,015,000 JPY
Extraordinary income
Extraordinary income
21,406,000 JPY
JPY
Profit (loss) before income taxes
-569,108,000 JPY
-649,015,000 JPY
Income taxes - current
1,461,000 JPY
1,844,000 JPY
Income taxes
1,461,000 JPY
1,844,000 JPY
Profit (loss)
-570,569,000 JPY
-650,860,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.